{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:38:23Z","timestamp":1768448303216,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-023-03170-0","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T16:01:41Z","timestamp":1682611301000},"page":"2861-2867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Local treatment in oligometastasis from breast cancer: an overview"],"prefix":"10.1007","volume":"25","author":[{"given":"Ana Manterola","family":"Burgaleta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Barco","family":"Burguete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lombardo Rosas","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkuden Burillo","family":"Nu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma As\u00edn","family":"Felipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1288-9356","authenticated-orcid":false,"given":"Fernando Arias","family":"de la Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"3170_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"3170_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000658-190707000-00001","volume":"46","author":"WS Halsted","year":"1907","unstructured":"Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1.","journal-title":"Ann Surg"},{"key":"3170_CR3","first-page":"3863","volume":"40","author":"B Fisher","year":"1980","unstructured":"Fisher B. Laboratory and clinical research in breast cancer\u2013a personal adventure: the David A Karnovsky memorial lecture. Cancer Res. 1980;40:3863\u201374.","journal-title":"Cancer Res"},{"key":"3170_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ. The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. Nat Rev Cancer. 2003;3:453\u20138.","journal-title":"Nat Rev Cancer"},{"key":"3170_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329\u201360.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"3170_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3170_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.breast.2006.11.002","volume":"16","author":"Metastatic breast cancer","year":"2007","unstructured":"Metastatic breast cancer. Recommendations proposal from the European school of oncology (ESO)-MBC task force. Breast. 2007;16(1):9\u201310.","journal-title":"Breast"},{"issue":"15","key":"3170_CR8","doi-asserted-by":"publisher","first-page":"e11512","DOI":"10.1200\/jco.2012.30.15_suppl.e11512","volume":"30","author":"SK Jain","year":"2012","unstructured":"Jain SK, Dorn PL, Chmura SJ, Weichselbaum RR, Hasan Y. Incidence and implications of oligometastatic breast cancer. J Clin Oncol. 2012;30(15):e11512\u2013e11512.","journal-title":"J Clin Oncol"},{"key":"3170_CR9","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1245\/s10434-012-2333-3","volume":"19","author":"DH Nguyen","year":"2012","unstructured":"Nguyen DH, Truong PT, Walter CV, Hayashi E, Christie JL, Chim CA. Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol. 2012;19:3028\u201334.","journal-title":"Ann Surg Oncol"},{"key":"3170_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ijrobp.2011.06.1901","volume":"81","author":"PL Dorn","year":"2011","unstructured":"Dorn PL, Meriwether A, LeMieux M, Weichselbaum RR, Chmura SJ, Hasan Y. Patterns of distant failure and progression in breast cancer: implications for the treatment of oligometastatic disease. Int J Radiat Oncol. 2011;81:643.","journal-title":"Int J Radiat Oncol"},{"key":"3170_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","volume":"22","author":"A Chalkidou","year":"2021","unstructured":"Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22:98\u2013106.","journal-title":"Lancet Oncol"},{"key":"3170_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.radonc.2021.09.031","volume":"164","author":"GA Viani","year":"2021","unstructured":"Viani GA, Gouveia AG, Louie AV, Korzeniowski M, Pavoni JF, Hamamura AC, et al. Stereotactic body radiotherapy to treat breast cancer oligometastases: a systematic review with meta-analysis. Radiother Oncol. 2021;164:245\u201350.","journal-title":"Radiother Oncol"},{"issue":"16_suppl","key":"3170_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","volume":"40","author":"SJ Chmura","year":"2022","unstructured":"Chmura SJ, Winter KA, Woodward WA, Woodward WA, Borges VF, Al-Hallaq HA, et al. NRG BR-002. JCO. 2022;40(16_suppl):1007.","journal-title":"JCO"},{"key":"3170_CR14","first-page":"90","volume":"28","author":"D Krug","year":"2021","unstructured":"Krug D, Vonthein R, Illen A, Denise Olbrich C, J\u00f6rg Barkhausen D, Richter J, et al. Metastases-directed radiotherapy in addition to standard systemic therapy in patients with oligometastatic breast cancer: study protocolfor a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021;28:90\u20136.","journal-title":"Clin Transl Radiat Oncol"},{"key":"3170_CR15","unstructured":"Trial of Superiority of Stereotactic Body Radiation Therapy in patients with breast cancer (STEREO-SEIN). ClinicalTrials.gov Identifier: NCT02089100"},{"key":"3170_CR16","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21:e18-28.","journal-title":"Lancet Oncol"},{"key":"3170_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2017.12.012","volume":"91","author":"NM deSouza","year":"2018","unstructured":"deSouza NM, Liu Y, Chiti A, Oprea-Lager D, Gebhart G, Van Beers BE, et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European organisation for research and treatment of cancer imaging group. Eur J Cancer. 2018;91:153\u201363.","journal-title":"Eur J Cancer"},{"key":"3170_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366.","journal-title":"Radiother Oncol"},{"key":"3170_CR19","unstructured":"E2-RADIatE European Platform for Data Collection. https:\/\/www.estro.org\/Science\/E2RADIATE."},{"key":"3170_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","volume":"126","author":"M Trovo","year":"2018","unstructured":"Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126:177\u201380.","journal-title":"Radiother Oncol"},{"key":"3170_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10549-008-0157-4","volume":"115","author":"MT Milano","year":"2009","unstructured":"Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115:601\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"3170_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","volume":"49","author":"S David","year":"2020","unstructured":"David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, et al. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast. 2020;49:55\u201362.","journal-title":"Breast"},{"key":"3170_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2021.06.012","volume":"161","author":"H Tan","year":"2021","unstructured":"Tan H, Cheung P, Louie AV, Myrehaug S, Niglas M, Atenafu EG, et al. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters. Radiother Oncol. 2021;161:159\u201365.","journal-title":"Radiother Oncol"},{"key":"3170_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","volume":"26","author":"M Scorsetti","year":"2016","unstructured":"Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, et al. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast. 2016;26:11\u20137.","journal-title":"Breast"},{"key":"3170_CR25","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3389\/fonc.2020.00987","volume":"10","author":"F Weykamp","year":"2020","unstructured":"Weykamp F, Konig L, Seidensaal K, Forster T, Hoegen P, Akbaba S, et al. Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol. 2020;10:987.","journal-title":"Front Oncol"},{"key":"3170_CR26","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3170_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","volume":"114","author":"S Harrow","year":"2022","unstructured":"Harrow S, Palma DA, Olson R, et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiation Oncol Biol Phys. 2022;114(4):611\u20136.","journal-title":"Int J Radiation Oncol Biol Phys"},{"key":"3170_CR28","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clon.2019.04.006","volume":"31","author":"D Xing","year":"2019","unstructured":"Xing D, Siva S, Hanna G. The abscopal effect of stereotactic radiotherapy and immunotherapy: fool\u2019s gold or El dorado? Clin Oncol. 2019;31:432\u201343.","journal-title":"Clin Oncol"},{"key":"3170_CR29","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","volume":"180","author":"AA Lugade","year":"2008","unstructured":"Lugade AA, Sorensen E, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180:3132\u20139.","journal-title":"J Immunol"},{"key":"3170_CR30","doi-asserted-by":"publisher","first-page":"9548","DOI":"10.1200\/JCO.2020.38.15_suppl.9548","volume":"38","author":"JW Welsh","year":"2020","unstructured":"Welsh JW, Chen D, Baas P, Chang JY, Verma V, Comeaux NI, et al. Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: pooled analysis of two randomized trials. J Clin Oncol. 2020;38:9548.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3170_CR31","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-17-3322","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, et al. Focal irradiation and systemic TGF\u03b2 blockade in metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(11):2493\u2013504.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3170_CR32","unstructured":"Harini D, de Silva PS, Petrone P, Neeson M, Tantalo D, Siva S, et al. Identification of peripheral blood biomarkers that predict response to the combination of radiotherapy and anti-PD1 checkpoint blockade in metastatic breast cancer. In Proceedings of the ASI 48th Annual Scientific Meeting of the Australian and New Zealand Society for Immunology, Adelaide, Australia, 8\u201312 December 2019"},{"key":"3170_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361\u201370.","journal-title":"Cancer Immunol Res"},{"key":"3170_CR34","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S1470-2045(19)30157-3","volume":"20","author":"SP Pitroda","year":"2019","unstructured":"Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019;20:e434\u201342.","journal-title":"Lancet Oncol"},{"key":"3170_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijrobp.2019.12.033","volume":"108","author":"SI Gutiontov","year":"2020","unstructured":"Gutiontov SI, Pitroda SP, Chmura SJ, Arina A, Weichselbaum RR, et al. Cytoreduction and the optimization of immune checkpoint inhibition with radiation therapy. Int J Radiat Oncol Biol Phys. 2020;108:17\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3170_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234\u201341.","journal-title":"Br J Radiol"},{"issue":"12","key":"3170_CR37","doi-asserted-by":"publisher","first-page":"e28650","DOI":"10.1371\/journal.pone.0028650","volume":"6","author":"YA Lussier","year":"2011","unstructured":"Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, et al. MicroRNA expression characterizes oligometastasis(es). PLoS ONE. 2011;6(12):e28650. https:\/\/doi.org\/10.1371\/journal.pone.0028650.","journal-title":"PLoS ONE"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03170-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:24:25Z","timestamp":1693211065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03170-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["3170"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03170-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent in nor required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}